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HCM-CMs display calcium irregularities
Hypertrophic cardiomyopathy (HCM) is estimated to be the most
prevalent hereditary heart disease in the world. In HCM patients,
the left ventricular wall of the heart thickens due to enlarged
cardiomyocytes (heart cells). The disease is a major cause of
disability and sudden cardiac death (SCD) in patients, particularly
those induced by arrhythmia. In Singapore, it is the most
prevalent genetic heart disease, affecting every 1 in 500 people.
The mechanism of HCM remains poorly defined, requiring
further understanding for improved therapeutic strategies. Due
to the challenge of obtaining cardiac biopsies from human
subjects, using induced pluripotent stem cells (iPSCs)
technology, we successfully generated a humanized HCM model
representative of an actual diseased heart cell to investigate the
molecular mechanisms involved in the disease pathology and the
link between arrhythmia and HCM.
Due to arrhythmia induced SCD being a profound manifestation of HCM, we hypothesize that ion 
channel irregularities are responsible for the symptoms and phenotype of HCM.
iPSCs were generated from blood of a HCM patient. Their pluripotency was confirmed by conducting
immunofluorescence staining of the following indicative markers: Oct4; a nuclear marker, and Tra-1-
60; a surface marker.
Immunostaining revealed that both Control- and HCM-iPSCs were pluripotent as they stained 
positive for these markers 
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Control- and HCM-iPSCs were subjected to cardiac differentiation. Initially, iPSC colonies were
dissociated into single cells and seeded into micro-wells. 24 hours later, these single cells had formed
aggregates known as embryoid bodies (EBs). The EBs were taken out of the micro-wells and treated
with specific growth factor and small molecules for 8 days after which they were plated. Contracting
clusters were visible by day 14 of differentiation. Throughout cardiac differentiation, the EBs
increased in size, particularly between days 2-4 and days 8-14.
The sarcomere is the basic contractile unit within cardiomyocytes. Staining against α-actinin
revealed disorganized sarcomeres in the HCM-CMs as compared to Control-CMs. Staining of the
nucleus with DAPI revealed an enlarged nucleus in HCM-CMs indicating that HCM-CMs were
probably undergoing cell division, due to re-initiation of the foetal program. Similar to the clinical
manifestation, HCM-CMs were larger in size as compared to Control-CMs.
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Figure 4. Phenotypic analysis of Control- and HCM-CMs. Left panel; pictographs of Control- and HCM-CMs stained against sarcomeric α-actinin and 
counterstained with DAPI. Note the disorganized sarcomeres and enlarged nucleus in HCM-CMs. Scale bar: 50 µm. Right panel; Box and Whisker plots 
showing differences in cell size between Control- and HCM-CMs. Box and Whisker plots presented as median with 10-90 percentile range. (n=100). 
*p<0.05 significantly different in comparison to Control-CMs. 
Figure 1. Image showing the contrast between a healthy 
patient’s heart (left) and a heart of a patient suffering from HCM 
(right).
Figure 2. Pictographs of Control- (left) and HCM-iPSCs (right) stained against Oct4 and Tra-1-60 and counterstained with DAPI (nuclear stain). 
Note the nuclear localization of Oct4 and the surface expression of Tra-1-60. Scale bar: 100 µm. 
Figure 3. Top panel; Pictographs of the cardiac differentiation procedure from day 0 to day 14. Note that not every single 
iPSC is incorporated into the EB. The yellow dotted circle highlights an aggregated EB. Bottom panel; Bar graphs showing 
changes in area and perimeter of the EBs (n=5) throughout cardiac differentiation. Bar graphs presented as mean ± SD. 
*p<0.05 significantly different between comparison groups. Abbreviation: NS- non-significant, D- day 
Quantitative gene expression analysis indicated that levels of potassium channels (KCNQ1, KCNE1,
KCNJ2) remained relatively similar between Control and HCM-CMs, however, levels of calcium
channels (RYR2, ATP2A2, CACNA1D, CACNA1C) were significantly up-regulated in HCM-CMs. The
levels of sarcomere genes (TNNT2 and MYL2) were also up-regulated in HCM-CMs. Calcium ions
regulate the contraction and relaxation of the cardiomyocytes. Calcium imaging suggested that
there were significantly more irregular calcium transients among the HCM-CMs as compared to
Control-CMs. These results indicate that HCM-CMs have abnormal calcium handling properties
which may give rise to arrhythmias in HCM patients.
Figure 5. Gene expression analysis and calcium imaging of Control- and HCM-CMs. Top panel; Bar graphs showing differences in expression
profile of 9 various genes in Control- and HCM-CMs. Bar graphs presented as mean ± SD (n=3 independent experiments). Calcium channel are
annotated in red font. Bottom panel; Left; representative images of spontaneous calcium traces in Control- and HCM-CMs. Note the irregular
calcium transients (red arrowheads) in HCM-CMs. Right; bar graph showing differences in prevalence of calcium irregularities between Control-
and HCM-CMs. Bar graph presented as mean ± SD (n=50 cells analysed per group). *p<0.05 significantly different in comparison to Control-CMs.
In conclusion, our results show that iPSC-CMs are indeed a good human model for recapitulating
the clinical manifestations of HCM, allowing us to observe the disease at a molecular level to further
understand its mechanisms. Our results have proven through examination of the relevant genes and
calcium imaging that HCM-CMs are found to have abnormal calcium handling properties, leading
to arrhythmia. Using our model, future work can be done to develop treatments that can stop or
resolve the calcium irregularities, and hence effectively lead to a decrease in the disease phenotypes
without obtaining actual cardiomyocytes. Our research has laid the foundation and direction for
potential treatments and research to be done, pointing towards multiple extensions of our work
that will increase our knowledge and efficiency at treating HCM and potentially other diseases as
well.
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